These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25801940)

  • 1. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.
    Moritoyo T
    Clin Ther; 2015 Aug; 37(8):1622-6. PubMed ID: 26342202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success.
    Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R
    Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint.
    Mani RB
    Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease.
    Schneider LS
    Alzheimers Dement; 2014 Mar; 10(2):247-50. PubMed ID: 24698029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
    Morant AV; Vestergaard HT; Lassen AB; Navikas V
    Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
    Tsukamoto K; Carroll KA; Onishi T; Matsumaru N; Brasseur D; Nakamura H
    Clin Ther; 2016 Mar; 38(3):574-81. PubMed ID: 26869192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposed agents in the Alzheimer's disease drug development pipeline.
    Bauzon J; Lee G; Cummings J
    Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future is now: model-based clinical trial design for Alzheimer's disease.
    Romero K; Ito K; Rogers JA; Polhamus D; Qiu R; Stephenson D; Mohs R; Lalonde R; Sinha V; Wang Y; Brown D; Isaac M; Vamvakas S; Hemmings R; Pani L; Bain LJ; Corrigan B; ;
    Clin Pharmacol Ther; 2015 Mar; 97(3):210-4. PubMed ID: 25669145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Differences During the ICH Regulatory Consultation Process Between the EU, US, and Japan.
    Torqui A; Macau AM
    Ther Innov Regul Sci; 2018 Jul; 52(4):438-441. PubMed ID: 29714552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
    Honig PK
    Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.